Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Decreases By 26.3%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decrease of 26.3% from the October 15th total of 79,800 shares. Based on an average trading volume of 64,100 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank purchased a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned approximately 0.21% of SAB Biotherapeutics as of its most recent SEC filing. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SABS. Chardan Capital reiterated a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Craig Hallum initiated coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target for the company. Oppenheimer reiterated an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Stock Up 12.6 %

Shares of SABS stock traded up $0.41 during trading on Thursday, reaching $3.67. 146,659 shares of the company’s stock were exchanged, compared to its average volume of 30,333. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a twelve month low of $2.16 and a twelve month high of $9.72. The firm’s fifty day moving average price is $2.93 and its 200-day moving average price is $2.98.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, research analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.